<DOC>
	<DOCNO>NCT01632826</DOCNO>
	<brief_summary>To provide pomalidomide access relapsed/refractory multiple myeloma subject likelihood benefit pomalidomide treatment medication commercially available</brief_summary>
	<brief_title>Pomalidomide ( POM ) Combination With Low Dose Dexamethasone ( LD-Dex ) Patients With Relapsed Refractory Multiple Myeloma</brief_title>
	<detailed_description>Several clinical study indicate pomalidomide activity relapse refractory multiple myeloma response rate range 30 % 60 % pomalidomide dose 2 mg/day and/or 4 mg/day .</detailed_description>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Pomalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 . Must document diagnosis relapse relapsed/refractory multiple myeloma measurable disease ( serum urine Mprotein ) 2 . Age ≥ 18 year 3 . Must least ≥ 2 prior antimyeloma therapy 4 . Must receive least 2 consecutive cycle lenalidomide bortezomib , either alone combination 5 . Must fail treatment last lenalidomidecontaining regimen last bortezomibcontaining regimen 6 . Must document disease progression last antimyeloma regimen 7 . Females childbearing potential ( FCBP ) must agree utilize two reliable form contraception simultaneously practice complete abstinence heterosexual contact least 28 day start drug , participate study least 28 day study treatment discontinuation . 8 . Males must agree use latex condom sexual contact FCBP participate study 28 day follow discontinuation study treatment . 1 . Peripheral Neuropathy ≥ Grade 2 2 . Nonsecretory multiple myeloma 3 . Previous therapy pomalidomide 4 . Use investigational agent within 28 day 5 half life ( whichever longer ) initiate study treatment 5 . Subjects condition require chronic steroid immunosuppressive treatment . 6 . Hypersensitivity thalidomide , lenalidomide dexamethasone 7 . Known Human Immunodeficiency Virus positive , active chronic Hepatitis A , B C 8 . Pregnant breastfeeding female 9 . Unacceptable hematological biochemical laboratory abnormality</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Relapsed</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>pomalidomide</keyword>
</DOC>